ReviewStem cell research & therapy2025
In vitro biomimetic models for respiratory diseases: progress in lung organoids and lung-on-a-chip.
Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Review
- iPSC-Derived Bronchial Airways-On-Chip for the Assessment of Cytokine Secretion Triggered by Volatile Organic Compounds.ACS biomaterials science & engineering · 2026Article
- The Impact of the Exposome on Epithelial Barriers: New Approach Methodologies for Translational Research.Thoracic research and practice · 2026Article
- Organ-on-a-Chip Technology and Global Multi-Omics: Current Applications and Future Directions.MedComm · 2026Review
- Organoids for disease modeling and treatment: state-of-the-art.Experimental hematology & oncology · 2026Review
- Lung organoids for respiratory diseases: overcoming translational hurdles in drug discovery and safety assessment.Frontiers in bioengineering and biotechnology · 2026Review
- Unveiling Particulate Matter-Lung Interactions from Static Models to Dynamic Lung-on-Chips.Research (Washington, D.C.) · 2026Review
- Advances in infection-immunity mechanisms and molecular regulatory networks in severe pneumonia-associated lung injury.Frontiers in immunology · 2026Review
- Tools of the trade: leveraging 3DFrontiers in pharmacology · 2026Review
- The mechanical microenvironment and lung stem cell fate.Frontiers in cell and developmental biology · 2026Review
- How the Fibrotic Lung Microenvironment Regulates Stem Cell Behavior: Immune Cues, Extracellular Matrix Remodeling, and Therapeutic Implications.Analytical cellular pathology (Amsterdam) · 2026Review
- Application and prospects of lung organ-on-a-chip in the development of new drugs.Biomedical engineering online · 2025Review
- Upscaling: efficient generation of human lung organoids from induced pluripotent stem cells using a stirring bioreactor.Frontiers in bioengineering and biotechnology · 2025Article
- Lung organoids as emerging models in idiopathic pulmonary fibrosis research: Current applications, challenges, and future directions.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory diseases pose a growing global public health challenge due to their rising incidence and mortality. Conventional cellular and animal models fall short in replicating the complex three-dimensional (3D) microenvironments of the lung and are limited by species differences, restricting their clinical relevance. Emerging technologies, such as lung organoids (LOs) and lung-on-a-chip (LOC), combine stem cell differentiation, microfluidic systems, and biomechanical cues to create advanced in vitro models that address these limitations. LOs leverage the innate ability of human pluripotent stem cells (hPSCs) to self-organize, faithfully mimicking lung development, cellular diversity, and the native tissue environment. In comparison, LOC platforms employ flexible biomaterials to recreate the respiratory microenvironment dynamically, enabling a detailed study of normal physiology and disease states. This review highlights recent advancements in LOs- and LOC-based models across five key respiratory conditions: infections, chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis (PF), and lung cancer. Furthermore, it discusses their capacity to deepen understanding of disease mechanisms, accelerate drug discovery, enhance pharmacological evaluation, and serve as comprehensive tools for respiratory research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.